Expression of STAT3 in Prostate Cancer Metastases

European Urology

Volumn 71, Issue 3, 2017, Pages 313-316

  Don Doncow, Nicholas ^a   Marginean, Felicia ^a,b   Coleman, Ilsa ^c   Nelson, Peter S ^c   Ehrnström, Roy ^b   Krzyzanowska, Agnieszka ^a   Morrissey, Colm ^d   Hellsten, Rebecka ^a   Bjartell, Anders ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c USA   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Castration resistant; Metastases; Prostate cancer; STAT3; Tissue microarray

Indexed keywords

INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; STAT3 PROTEIN; BENZAMIDE DERIVATIVE; IL6R PROTEIN, HUMAN; N-PHENYL-N-(1-(PIPERIDINE-1-CARBONYL)CYCLOHEXYL)BENZAMIDE; PHOSPHOPROTEIN; PIPERIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN; TRANSCRIPTOME;

ARTICLE; AUTOPSY; BONE METASTASIS; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COMPARATIVE STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; OSTEOBLAST; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR MICROENVIRONMENT; VISCERAL METASTASIS; ADENOCARCINOMA; BONE TUMOR; GENETICS; LIVER TUMOR; LYMPH NODE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SECONDARY;

ADENOCARCINOMA; AUTOPSY; BENZAMIDES; BONE NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM METASTASIS; PHOSPHOPROTEINS; PIPERIDINES; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, INTERLEUKIN-6; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTOME;

EID: 84998843866     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.06.018     Document Type: Article

References (10)

1. [1] Bishop, J.L., Thaper, D., Zoubeidi, A., The multifaceted roles of STAT3 signaling in the progression of prostate cancer. Cancers 6 (2014), 829–859.
2. [2] Canesin, G., Evans-Axelsson, S., Hellsten, R., et al. The STAT3 inhibitor galiellalactone effectively reduces tumor growth and metastatic spread in an orthotopic xenograft mouse model of prostate cancer. Eur Urol 69 (2016), 400–404.
3. [3] Tam, L., McGlynn, L.M., Traynor, P., Mukherjee, R., Bartlett, J.M., Edwards, J., Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 97 (2007), 378–383.
4. [4] Mora, L.B., Buettner, R., Seigne, J., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62 (2002), 6659–6666.
5. [5] Shariat, S.F., Andrews, B., Kattan, M.W., Kim, J., Wheeler, T.M., Slawin, K.M., Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58 (2001), 1008–1015.
6. [6] Roudier, M.P., True, L.D., Higano, C.S., et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34 (2003), 646–653.
7. [7] Halabi, S., Kelly, W.K., Ma, H., et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 34 (2016), 1652–1659.
8. [8] Akfirat, C., Zhang, X., Ventura, A., et al. Tumor cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol 230 (2013), 291–297.
9. [9] Lu, Y., Zhang, J., Dai, J., et al. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis 21 (2004), 399–408.
10. [10] Yu, S.-H., Zheng, Q., Esopi, D., et al. A paracrine role for IL6 in prostate cancer patients: lack of production by primary or metastatic tumor cells. Cancer Immunol Res 3 (2015), 1175–1184.